Category: Neurofibromatosis

As of early 2025, two MEK inhibitor medications have received FDA approval for the treatment of certain neurofibromas. The advent of these drugs has transformed the treatment landscape for individuals with neurofibromatosis type 1 (NF1), offering a targeted, non-surgical option for specific tumor types. This is a significant shift from previous approaches and addresses the key question of **what medication is used to treat neurofibromas?**

Chronic pain is a significant symptom for many with neurofibromatosis, with some reports indicating its prevalence as high as 70% in certain populations. Knowing **what pain medication is used for neurofibromatosis** is complex, as standard analgesics are often ineffective against the distinct neuropathic pain caused by tumor growth. Effective treatment requires a multifaceted approach, often combining different medications and complementary therapies.

Neurofibromatosis type 1 (NF1), a genetic disorder that causes tumors to grow on nerves, affects approximately 1 in every 3,000 people worldwide [1.6.3, 1.6.2]. For those affected, a critical question arises: what is the best medicine for neurofibroma?